Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Should You Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $9.16, but opened at $10.00. Theravance Biopharma shares last traded at $10.83, with a volume of 357,052 shares trading hands.

Analyst Ratings Changes

Several brokerages have issued reports on TBPH. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $11.33.

Theravance Biopharma Stock Down 1.0%

The company has a market cap of $550.51 million, a P/E ratio of -10.90 and a beta of -0.10. The business has a 50-day moving average price of $9.23 and a two-hundred day moving average price of $9.37.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. As a group, sell-side analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at $3,330,342. The trade was a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently made changes to their positions in the stock. Aquatic Capital Management LLC acquired a new position in Theravance Biopharma in the fourth quarter valued at about $25,000. GAMMA Investing LLC grew its stake in Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 3,281 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Theravance Biopharma in the fourth quarter valued at about $69,000. AQR Capital Management LLC acquired a new position in Theravance Biopharma in the first quarter valued at about $101,000. Finally, Teacher Retirement System of Texas acquired a new position in Theravance Biopharma in the fourth quarter valued at about $103,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.